Bedrijfsoverzicht
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, oral, and small molecule therapies that target the signal transducer and activator of transcription 3 (STAT3) pathway to address inflammatory and proliferative diseases with significant unmet medical needs. The company operates within the healthcare sector, specifically inside the biotechnology industry, where it focuses on early-stage drug discovery and development rather than commercialization of approved products. Its financial scale is defined by a market capitalization of $27.21M and a workforce consisting of 12 employees, indicating a very small, early-stage operational footprint typical of pre-revenue biotech firms. The combination of a market cap in the high millions and zero reported revenue suggests that the company's value is derived almost exclusively from its pipeline potential and intellectual property rather than current sales performance or established market share.
Financiële gezondheid
The financial statements for Tvardi Therapeutics, Inc. show a net income of $-18,214,000 and an EBITDA of $-26,653,000, while revenue is listed as N/A, indicating the company has not yet generated significant commercial sales to offset its high operational expenditures. The substantial gap between the negative net income and the even more negative EBITDA reveals a cost structure heavily influenced by non-cash items or specific accounting adjustments, though the primary driver remains the immense cash burn required for clinical trials and R&D. The company's free cash flow stands at $-15,216,500, which signifies a negative financial flexibility where the firm must rely entirely on external capital sources to fund its operations and continue its drug development programs. All three margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the standard financial profile of a clinical-stage biotechnology company that has not yet reached a revenue-generating phase. In terms of balance sheet strength, the company holds $30.81M in cash against only $201,000 in debt, resulting in a debt-to-equity ratio of 0.96 which indicates a leveraged position relative to its equity but one that is primarily funded by cash reserves rather than interest-bearing liabilities. The current ratio is 2.86, which suggests strong short-term liquidity as the company possesses ample current assets to cover its immediate obligations without requiring emergency financing. Return on Equity is -237.8% and return on assets is -49.7%, metrics that reveal the company is currently destroying shareholder value through cash burn rather than generating returns, a common but risky characteristic of pre-commercial biotech ventures.
Waarderingsbeoordeling
The valuation metrics for Tvardi Therapeutics, Inc. present a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is listed as -1.11, implying that the market is pricing in continued negative earnings rather than a trajectory toward profitability in the immediate future. The price-to-book ratio is 1.30, indicating that the market values the company at 30% above its net asset value, a premium that investors place on the potential of its STAT3-targeting therapies despite the current lack of revenue. Since the price-to-sales ratio is N/A and the EV/EBITDA is 0.13, these alternative valuation metrics suggest that the company is valued almost entirely on its asset base and future pipeline potential rather than current earnings power or sales multiples. The stock's price range over the last year has seen extreme volatility, with a 52-week high of $43.65 and a 52-week low of $2.75, meaning the current price sits significantly below the recent peak but far above the yearly trough. The beta value is listed as N/A, which prevents a direct comparison of its price volatility relative to the broader market but highlights the inherent risk associated with small-cap biotechnology stocks that lack historical pricing data.
Growth & Income
Tvardi Therapeutics, Inc. reports revenue growth of N/A and earnings growth of N/A, as the company has not yet established a baseline of recurring revenue to calculate year-over-year growth rates. Because the company has not generated positive earnings, there is no sustainable dividend yield or payout ratio to report, and the 0.0% payout ratio reflects the reality that the firm retains all available capital to fund its research and development rather than distributing income to shareholders. Consequently, the company reinvests its limited cash resources directly into its clinical-stage pipeline, aiming to advance its STAT3 therapies through regulatory approval before any income generation can occur. The overall growth and income profile is characterized by high risk and zero current income, with the entire financial strategy focused on capitalizing the asset base to achieve a commercial milestone rather than delivering quarterly returns or dividend payments.